Results 21 to 30 of about 75,341 (263)
Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response
Scientific Reports, 2023 Glutamatergic dysfunction is associated with failure to respond to antipsychotic medication in individuals with schizophrenia. Our objective was to combine neurochemical and functional brain imaging methods to investigate glutamatergic dysfunction and ...
Elias D. Mouchlianitis +5 more
doaj +1 more source
Trends in Psychiatry and Psychotherapy, 2021 Objective To investigate epidemiological factors related to treatment-resistant schizophrenia (TRS) in Northeast Brazil, a region where data about mental health are still scarce.
Douglas de Sousa Soares +4 more
doaj +1 more source
Restoration of Sp4 in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in Sp4 Hypomorphic Mice. [PDF]
, 2015 BackgroundKetamine produces schizophrenia-like behavioral phenotypes in healthy people. Prolonged ketamine effects and exacerbation of symptoms after the administration of ketamine have been observed in patients with schizophrenia.
Buell, Mahalah R +7 more
core +1 more source
Informed consent decision-making in deep brain stimulation [PDF]
, 2018 Deep brain stimulation (DBS) has proved useful for several movement disorders (Parkinson’s disease, essential tremor, dystonia), in which first and/or second line pharmacological treatments were inefficacious.
Appelbaum +6 more
core +2 more sources
Treatment-Resistant Schizophrenia
Focus, 2020 Although, gratifyingly, research on the treatment of schizophrenia has increasingly focused on first-episode and prodromal patient populations, it is still recognized that many patients with more chronic illnesses exhibit a suboptimal response to treatments.
openaire +3 more sources
Evaluation of Treatment-Resistant Schizophrenia [PDF]
Schizophrenia Bulletin, 1997 A systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of clozapine, risperidone, and olanzapine. The need for accurate evaluation will increase with the introduction of the next generation of antipsychotic medications.
R R, Conley, R W, Buchanan
openaire +2 more sources
Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2019 According to modern data, about a third of patients suffering from schizophrenia are considered treatment resistant. The metabolism of about 20% of medicines and mainly psychotropic drugs is caused by the isoenzyme CYP2D6.
D. N. Sosin +4 more
doaj +1 more source
Biomedicines, 2023 Clozapine is considered the gold standard for patients with treatment-resistant schizophrenia (TRS) who have previously tried other antipsychotics at adequate doses (two or more, with at least one being atypical).
Vjekoslav Peitl +5 more
doaj +1 more source
Clozapine in treatment-resistant schizophrenia [PDF]
British Journal of Psychiatry, 2017 In an era when 11 meta-analyses are published every day, there are sometimes 2 on the same topic which do not agree. As such a situation can be very confusing, systematic reviewers should discuss their findings in the light of existing reviews to make the differences understandable to readers.[1 ...
Myrto, Samara, Stefan, Leucht
openaire +2 more sources
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. [PDF]
, 2010 Despite significant research efforts aimed at understanding the neurobiological underpinnings of psychiatric disorders, the diagnosis and the evaluation of treatment of these disorders are still based solely on relatively subjective assessment of ...
Alexander, Robert C. +15 more
core +9 more sources